Jeff Yass’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,388
| Closed | -$527K | – | 13238 |
|
|
2025
Q4 | $527K | Sell |
2,388
-131,123
| -98% | -$21.2M | ﹤0.01% | 8659 |
|
|
2025
Q3 | $12.8M | Buy |
133,511
+78,671
| +143% | +$5.02M | ﹤0.01% | 2719 |
|
|
2025
Q2 | $2.67M | Sell |
54,840
-287,636
| -84% | -$6.91M | ﹤0.01% | 5196 |
|
|
2025
Q1 | $7.38M | Buy |
342,476
+299,853
| +704% | +$6.66M | ﹤0.01% | 2954 |
|
|
2024
Q4 | $1.15M | Buy |
+42,623
| New | +$693K | ﹤0.01% | 6617 |
|
|
2024
Q1 | – | Sell |
-644
| Closed | -$10.2K | – | 12258 |
|
|
2023
Q4 | $10.2K | Buy |
+644
| New | +$10.3K | ﹤0.01% | 12069 |
|
|
2023
Q3 | – | Sell |
-1,213
| Closed | -$23.8K | – | 12076 |
|
|
2023
Q2 | $27.4K | Sell |
1,213
-4,012
| -77% | -$94.3K | ﹤0.01% | 11552 |
|
|
2023
Q1 | $133K | Buy |
+5,225
| New | +$148K | ﹤0.01% | 11030 |
|
|
2022
Q1 | – | Sell |
-1,112
| Closed | -$28K | – | 13038 |
|
|
2021
Q4 | $28K | Buy |
+1,112
| New | +$34.6K | ﹤0.01% | 12757 |
|
|
2020
Q2 | – | Sell |
-2,177
| Closed | -$141K | – | 10172 |
|
|
2020
Q1 | $108K | Buy |
2,177
+1,674
| +333% | +$100K | ﹤0.01% | 9267 |
|
|
2019
Q4 | $39K | Sell |
503
-135
| -21% | -$6.18K | ﹤0.01% | 9399 |
|
|
2019
Q3 | $25K | Buy |
+638
| New | +$21.4K | ﹤0.01% | 9919 |
|
|
2017
Q3 | – | Sell |
-2,331
| Closed | -$350K | – | 8850 |
|
|
2017
Q2 | $350K | Buy |
+2,331
| New | +$322K | ﹤0.01% | 7295 |
|
|
2017
Q1 | – | Sell |
-1,011
| Closed | -$210K | – | 9001 |
|
|
2016
Q4 | $210K | Buy |
+1,011
| New | +$210K | ﹤0.01% | 8579 |
|
|
2016
Q3 | – | Sell |
-503
| Closed | -$104K | – | 8426 |
|
|
2016
Q2 | $104K | Buy |
+503
| New | +$122K | ﹤0.01% | 8003 |
|
Jeff Yass's CDTX Position: Q1 2026 in Review
Jeff Yass sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 2,388 shares — an estimated $527K sold.
Jeff Yass first reported a position in CDTX in Q2 2016 and held it in 15 quarters. The position peaked at $12.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Jeff Yass reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Jeff Yass sold 2,388 Cidara Therapeutics shares in Q1 2026, an estimated $527K.
- Jeff Yass first reported a position in Cidara Therapeutics in Q2 2016 and held it in 15 quarters.
- Jeff Yass's Cidara Therapeutics position peaked at $12.8M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.